Serum selenium concentration, glutathione peroxidase activity and lipid peroxides in a co-twin control study on multiple sclerosis. 1989

H Korpela, and E Kinnunen, and J Juntunen, and J Kumpulainen, and M Koskenvuo
Department of Physiology, University of Oulu, Finland.

Serum selenium concentration, glutathione peroxidase activity and lipid peroxides were determined in patients with multiple sclerosis (MS). The series consisted of 13 same-sexed twin pairs derived from the Finnish Twin Cohort of 15,815 pairs. Fourteen subjects had a definite and 1 a probable MS, and their 11 co-twins showed no evidence of central nervous system disease. No statistical differences were observed, but the 3 patients with active progressive MS had a higher mean level of lipid peroxides than the rest of the patients. We suggest that serum lipid peroxidation may be involved in the activity of MS.

UI MeSH Term Description Entries
D008054 Lipid Peroxides Peroxides produced in the presence of a free radical by the oxidation of unsaturated fatty acids in the cell in the presence of molecular oxygen. The formation of lipid peroxides results in the destruction of the original lipid leading to the loss of integrity of the membranes. They therefore cause a variety of toxic effects in vivo and their formation is considered a pathological process in biological systems. Their formation can be inhibited by antioxidants, such as vitamin E, structural separation or low oxygen tension. Fatty Acid Hydroperoxide,Lipid Peroxide,Lipoperoxide,Fatty Acid Hydroperoxides,Lipid Hydroperoxide,Lipoperoxides,Acid Hydroperoxide, Fatty,Acid Hydroperoxides, Fatty,Hydroperoxide, Fatty Acid,Hydroperoxide, Lipid,Hydroperoxides, Fatty Acid,Peroxide, Lipid,Peroxides, Lipid
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009103 Multiple Sclerosis An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) MS (Multiple Sclerosis),Multiple Sclerosis, Acute Fulminating,Sclerosis, Disseminated,Disseminated Sclerosis,Sclerosis, Multiple
D004200 Diseases in Twins Disorders affecting TWINS, one or both, at any age. Diseases in Twin,Twin, Diseases in,Twins, Diseases in,in Twin, Diseases,in Twins, Diseases
D005260 Female Females
D005979 Glutathione Peroxidase An enzyme catalyzing the oxidation of 2 moles of GLUTATHIONE in the presence of HYDROGEN PEROXIDE to yield oxidized glutathione and water. Cytosolic Glutathione Peroxidase,Glutathione Lipoperoxidase,Selenoglutathione Peroxidase,Glutathione Peroxidase, Cytosolic,Lipoperoxidase, Glutathione,Peroxidase, Glutathione,Peroxidase, Selenoglutathione
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

H Korpela, and E Kinnunen, and J Juntunen, and J Kumpulainen, and M Koskenvuo
January 1986, Acta pharmacologica et toxicologica,
H Korpela, and E Kinnunen, and J Juntunen, and J Kumpulainen, and M Koskenvuo
January 1988, Biomedica biochimica acta,
H Korpela, and E Kinnunen, and J Juntunen, and J Kumpulainen, and M Koskenvuo
April 1988, Zeitschrift fur die gesamte Hygiene und ihre Grenzgebiete,
H Korpela, and E Kinnunen, and J Juntunen, and J Kumpulainen, and M Koskenvuo
January 1988, Annals of clinical research,
H Korpela, and E Kinnunen, and J Juntunen, and J Kumpulainen, and M Koskenvuo
October 1980, Journal of the neurological sciences,
H Korpela, and E Kinnunen, and J Juntunen, and J Kumpulainen, and M Koskenvuo
January 1983, European neurology,
H Korpela, and E Kinnunen, and J Juntunen, and J Kumpulainen, and M Koskenvuo
February 1984, Journal of animal science,
H Korpela, and E Kinnunen, and J Juntunen, and J Kumpulainen, and M Koskenvuo
January 1987, Archives of environmental health,
H Korpela, and E Kinnunen, and J Juntunen, and J Kumpulainen, and M Koskenvuo
May 1988, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie,
H Korpela, and E Kinnunen, and J Juntunen, and J Kumpulainen, and M Koskenvuo
February 2003, Clinical chemistry and laboratory medicine,
Copied contents to your clipboard!